DNA methyltransferase inhibitor, Guadecitabine (SGI-110), was tested on wild type GISTs, pheochromocytoma, and paraganglioma associated with SDH deficiency in hereditary leiomyomatosis and renal cell carcinoma (NCT03165721). This evidence concerns the gene SDHB and hereditary clear cell renal cell carcinoma.